Non-small cell lung cancer
Conditions
Interventions
Gold Standard:Gold Standard: Sanger sequencing
Reference Standard:cobas EGFR Mutation Test V2 (Roche Diagnostics GmbH,State instrument injection 20193401515) and Vysis ALK Break Apart FISH Probe Kit (
EGFR/ALK 
Combo 
Detection 
Kit 
(Hybrid 
Capture-Based 
Sponsors
Beijing Chest Hospital Affiliated to Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Subjects aged 18 years or above were selected, regardless of gender; 2. Subjects with clinically diagnosed non-small cell lung cancer (NSCLC) by cytology or histology; 3. More than 10 pieces of wax roll, 3-5 µ m thick samples, more than 2 pieces of white pieces, tumor cells accounted for more than 20%, necrosis tissue area < 10%. 4. Select samples within 2 years; 5. Interference samples: samples of small cell lung cancer or benign tumor.
Exclusion criteria
Exclusion criteria: 1. The sample size is insufficient to meet the test requirements; 2. Samples not kept in accordance with the instructions; 3. Samples with incomplete case information (including gender, age, diagnosis results, imaging diagnosis, pathological diagnosis and other demographic data, etc.) 4. Samples that the researchers think need to be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Positive coincidence rate;Negative coincidence rate;The total coincidence rate;Kappa value; | — |
Countries
China
Contacts
Public ContactCuicui Wang
HaploX Biotechnology Co., Ltd.
Outcome results
None listed